secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001558370-23-013235
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics promotes Christopher Frankenfield to COO; $500k salary, 150k option grant
--------------------------------------------------------------------------------

- Christopher Frankenfield promoted from Chief Legal & Admin Officer to COO effective Aug 3, 2023.
- New annual base salary of $500,000; target bonus set at 50% of base salary.
- Granted option to purchase 150,000 shares of common stock, vesting monthly over 4 years.
- Frankenfield previously served as Chief Legal & Admin Officer since Aug 2022 and at Blueprint Medicines.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023013235/0001558370-23-013235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023013235/xlo-20230803x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-013235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer